A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the optimal dose of fixed-dose combination of
candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the
combination therapy compared to each of the monotherapy in patients with essential
hypertension.